SGLT2 Inhibitors Linked to Lower Epilepsy Risk - Takeaways - MDSpire

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

Real-world cohort data show lower epilepsy risk vs DPP-4 inhibitors in older patients with type 2 diabetes

  • By

  • Kathryn Wighton

  • April 7, 2026

  • 3 min

Share

  • 1

    SGLT2 inhibitors are linked to a 45% lower risk of late-onset epilepsy in patients aged 60 and older compared to DPP-4 inhibitors.

  • 2

    Patients using SGLT2 inhibitors showed a 62% lower risk of status epilepticus and a 37% lower risk of starting antiseizure medications.

  • 3

    Cumulative incidence curves indicated significant differences in epilepsy risk between SGLT2 and DPP-4 inhibitor groups throughout the follow-up.

  • 4

    Subgroup analyses revealed lower risks of late-onset epilepsy in patients with prior stroke and dementia when using SGLT2 inhibitors.

  • 5

    The study's observational design limits causality conclusions, and several limitations were noted, including reliance on coded diagnoses.

Original Source(s)

SGLT2 Inhibitors Linked to Lower Epilepsy Risk

  • by Kathryn Wighton

  • April 7, 2026

Related Content

Highlighting the value of polymyography in childhood onset movement disorders

GLP-1 Drugs Tied to Lower Addiction Risk

In a target-trial emulation of more than 600,000 veterans, GLP-1 RA initiators saw fewer new substance use disorders—and patients with existing SUDs had fewer overdoses, hospitalizations, and deaths.

Synergistic neuroplasticity from synchronous Taiji Yunshou and tDCS in stroke: an fNIRS study of cortical activation and cross-subject hemodynamic brain network